Product, Net was the largest of Biogen Inc.’s 3 reported lines in fiscal 2020, at $2.69B — 80% of $3.38B.
| Product and Service | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product, Net | $2.38B | $2.64B | $2.62B | $10.35B | $2.52B | $2.76B | $2.78B | $2.68B | $2.88B | $2.89B | $2.90B | $2.80B | $2.69B | ||||||
| Avonex | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Tysabri | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Revenues From Anti-Cd20 Therapeutic Programs | $340.60M | $397.10M | $406.50M | — | $443.20M | $490.40M | $511.70M | $517.40M | $576.40M | $595.80M | $520.40M | $478.30M | $560.10M | ||||||
| Rituxan | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Other | — | — | — | — | — | — | — | $292.40M | $160.00M | $109.60M | $109.30M | $407.60M | $125.70M | ||||||
| Other Revenue | $90.00M | $41.60M | $48.80M | — | $164.40M | $108.60M | $147.20M | — | — | — | — | — | — | ||||||
| Fumaderm | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Fampyra | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Other Products | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Total | $2.81B | $3.08B | $3.08B | $10.35B | $3.13B | $3.36B | $3.44B | $3.49B | $3.62B | $3.60B | $3.53B | $3.68B | $3.38B |
In fiscal 2020, which ended September 30, 2020, the 3 revenue lines Biogen Inc. reported in this breakdown added up to $3.38B. That was down 8.3% from $3.68B in fiscal 2020. Product, Net was the largest revenue line, at $2.69B or 79.7% of the total, followed by Revenues From Anti-Cd20 Therapeutic Programs ($560.10M, 16.6%) and Other ($125.70M, 3.7%). Together, the two largest revenue lines made up 96.3% of this total.
Compared with fiscal 2020, Revenues From Anti-Cd20 Therapeutic Programs grew the fastest, rising 17.1% to $560.10M. Other fell the most, down 69.2% to $125.70M.
The table also keeps 7 revenue lines that Biogen Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 7 discontinued" beneath the table to see them. This breakdown covers 19 fiscal years between 2008 and 2020, as reported in Biogen Inc.'s annual filings.
U.S was the largest of Biogen Inc.’s 4 reported lines in fiscal 2017, at $7.02B — 68% of $10.35B.
| Geography | FY 2009 | FY 2011 | FY 2012 | FY 2014 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| U.S | — | $5.57B | $6.55B | $7.06B | $7.02B | |||
| United States | — | — | — | — | — | |||
| Europe | — | $1.38B | $2.17B | $2.24B | $2.84B | |||
| Segment, Geographical, Groups Of Countries, Group One | — | — | — | — | — | |||
| Germany | — | $811.80M | — | — | — | |||
| Segment Geographical Groups Of Countries Group Other | — | $328.20M | $333.30M | $313.00M | $332.70M | |||
| Asia | — | $112.80M | $143.70M | $217.30M | $160.10M | |||
| Foreign Tax Authority | — | $78.30M | — | — | — | |||
| Italy | $53.50M | — | — | — | — | |||
| Segment Geographical Groups Of Countries Group Three | — | — | — | — | — | |||
| Total | $53.50M | $8.28B | $9.19B | $9.82B | $10.35B |
In fiscal 2017, which ended December 31, 2017, the 4 regions Biogen Inc. reported in this breakdown added up to $10.35B. That was up 5.4% from $9.82B in fiscal 2016. U.S was the largest region, at $7.02B or 67.8% of the total, followed by Europe ($2.84B, 27.5%) and Segment Geographical Groups Of Countries Group Other ($332.70M, 3.2%). Together, the two largest regions made up 95.2% of this total.
Compared with fiscal 2016, Europe grew the fastest, rising 27.2% to $2.84B. U.S fell the most, down 0.5% to $7.02B.
The table also keeps 6 regions that Biogen Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 8 fiscal years between 2009 and 2017, as reported in Biogen Inc.'s annual filings.
Biogen Inc. (BIIB) breaks its revenue down by revenue line and region. In fiscal 2020, its largest revenue line was Product, Net, with $2.69B or 79.7% of the total, followed by Revenues From Anti-Cd20 Therapeutic Programs at $560.10M (16.6%).
Product, Net was Biogen Inc.'s largest revenue line in fiscal 2020, with $2.69B in revenue, 79.7% of the $3.38B reported across its 3 revenue lines.
U.S was Biogen Inc.'s largest region in fiscal 2017, with $7.02B in revenue, 67.8% of the $10.35B reported across its 4 regions.
Of the Biogen Inc. regions reported in both fiscal 2016 and fiscal 2017, and making up at least 2% of the total, Europe grew the fastest, rising 27.2% from $2.24B to $2.84B.
Every figure is taken from Biogen Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2008 to 2020. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.